

Robert Ball

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3166223/publications.pdf>

Version: 2024-02-01

94
papers

4,147
citations

126708

33
h-index

123241

61
g-index

95
all docs

95
docs citations

95
times ranked

3659
citing authors

#	ARTICLE	IF	CITATIONS
1	Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. JAMA - Journal of the American Medical Association, 2009, 302, 750.	3.8	398
2	Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatric Infectious Disease Journal, 2004, 23, 287-294.	1.1	323
3	Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety, 2005, 28, 981-1007.	1.4	204
4	The FDA's sentinel initiative—A comprehensive approach to medical product surveillance. Clinical Pharmacology and Therapeutics, 2016, 99, 265-268.	2.3	182
5	Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring. Vaccine, 2009, 27, 2114-2120.	1.7	161
6	The FDA Sentinel Initiative — An Evolving National Resource. New England Journal of Medicine, 2018, 379, 2091-2093.	13.9	137
7	Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine. JAMA - Journal of the American Medical Association, 2005, 294, 2720.	3.8	123
8	The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety. Pharmacoepidemiology and Drug Safety, 2012, 21, 9-11.	0.9	108
9	Postlicensure Monitoring of Intussusception After RotaTeq Vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics, 2008, 121, 1206-1212.	1.0	106
10	Use of data mining at the Food and Drug Administration. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 428-434.	2.2	100
11	The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents. Pediatrics, 2012, 129, 248-255.	1.0	99
12	The Food and Drug Administration's Post-licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiology and Drug Safety, 2012, 21, 291-297.	0.9	94
13	Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991-2001. MMWR Surveillance Summaries, 2003, 52, 1-24.	18.6	90
14	Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 631-638.	2.2	88
15	Adverse event reports following vaccination for Lyme disease: December 1998—July 2000. Vaccine, 2002, 20, 1603-1608.	1.7	79
16	Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion, 2012, 52, 2113-2121.	0.8	77
17	Comparing data mining methods on the VAERS database. Pharmacoepidemiology and Drug Safety, 2005, 14, 601-609.	0.9	66
18	Transfusion-associated circulatory overload (<scp>TACO</scp>) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011. Vox Sanguinis, 2014, 106, 144-152.	0.7	64

#	ARTICLE	IF	CITATIONS
19	Adverse Events After Inactivated Influenza Vaccination Among Children Less Than 2 Years of Age: Analysis of Reports From the Vaccine Adverse Event Reporting System, 1990-2003. <i>Pediatrics</i> , 2005, 115, 453-460.	1.0	62
20	Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. <i>American Journal of Epidemiology</i> , 2012, 175, 1120-1128.	1.6	62
21	Kawasaki Disease After Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 943-947.	1.1	56
22	Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. <i>Vaccine</i> , 2007, 25, 4244-4251.	1.7	52
23	Evaluation of Guillain-Barré Syndrome Among Recipients of Influenza Vaccine in 2000 and 2001. <i>American Journal of Preventive Medicine</i> , 2010, 39, 296-304.	1.6	49
24	Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS). <i>Drug Safety</i> , 2008, 31, 667-674.	1.4	47
25	Immunization-Safety Monitoring Systems for the 2009 H1N1 Monovalent Influenza Vaccination Program. <i>Pediatrics</i> , 2011, 127, S78-S86.	1.0	45
26	HLA type and immune response to <i>Borrelia burgdorferi</i> outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. <i>Arthritis and Rheumatism</i> , 2009, 60, 1179-1186.	6.7	44
27	Surveillance for Guillain-Barré Syndrome After Influenza Vaccination Among the Medicare Population, 2009-2010. <i>American Journal of Public Health</i> , 2012, 102, 1921-1927.	1.5	42
28	Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. <i>Clinical Infectious Diseases</i> , 2004, 38, 771-779.	2.9	41
29	Vaccine adverse event text mining system for extracting features from vaccine safety reports. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 1011-1018.	2.2	41
30	Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Event Reporting System. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 819-824.	2.4	39
31	Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. <i>American Journal of Hematology</i> , 2013, 88, 1035-1040.	2.0	38
32	Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology. <i>Journal of Biomedical Informatics</i> , 2018, 83, 73-86.	2.5	38
33	Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): A Case Study of Febrile Seizures after a 2010-2011 Seasonal Influenza Virus Vaccine. <i>Drug Safety</i> , 2013, 36, 547-556.	1.4	37
34	Vaccine Risk Perception Among Reporters of Autism After Vaccination: Vaccine Adverse Event Reporting System 1990-2001. <i>American Journal of Public Health</i> , 2004, 94, 990-995.	1.5	35
35	Evaluating adverse events after vaccination in the Medicare population. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 753-761.	0.9	35
36	Can Network Analysis Improve Pattern Recognition Among Adverse Events Following Immunization Reported to VAERS?. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 271-278.	2.3	34

#	ARTICLE	IF	CITATIONS
37	Chart-Confirmed Guillain-Barre Syndrome After 2009 H1N1 Influenza Vaccination Among the Medicare Population, 2009-2010. <i>American Journal of Epidemiology</i> , 2013, 178, 962-973.	1.6	32
38	Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. <i>Vaccine</i> , 2008, 26, 6349-6360.	1.7	29
39	A global regulatory science agenda for vaccines. <i>Vaccine</i> , 2013, 31, B163-B175.	1.7	29
40	Rapid Emergence of Free-Riding Behavior in New Pediatric Immunization Programs. <i>PLoS ONE</i> , 2010, 5, e12594.	1.1	27
41	Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 913-920.	2.2	26
42	A <sc>COVID</sc>-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 827-837.	0.9	26
43	Outpatient transfusions and occurrence of serious noninfectious transfusion-related complications among US elderly, 2007-2008: utility of large administrative databases in blood safety research. <i>Transfusion</i> , 2012, 52, 1968-1976.	0.8	25
44	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. <i>Npj Digital Medicine</i> , 2021, 4, 170.	5.7	25
45	Methods of ensuring vaccine safety. <i>Expert Review of Vaccines</i> , 2002, 1, 161-168.	2.0	24
46	Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. <i>Statistics in Medicine</i> , 2005, 24, 551-562.	0.8	24
47	Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 793-797.	2.2	24
48	Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. <i>Vaccine</i> , 2009, 27, 290-297.	1.7	23
49	A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports. <i>Journal of Biomedical Informatics</i> , 2016, 62, 78-89.	2.5	23
50	Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14. <i>Vaccine</i> , 2017, 35, 2986-2992.	1.7	22
51	Emerging technologies and their impact on regulatory science. <i>Experimental Biology and Medicine</i> , 2022, 247, 1-75.	1.1	22
52	Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. <i>Journal of Rheumatology</i> , 2004, 31, 2181-8.	1.0	22
53	“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?. <i>Drug Safety</i> , 2022, 45, 429-438.	1.4	21
54	Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990-2008. <i>Vaccine</i> , 2011, 29, 1319-1323.	1.7	20

#	ARTICLE	IF	CITATIONS
55	Randomized, observational, interventional, and real-world "What's in a name?. Pharmacoepidemiology and Drug Safety, 2020, 29, 1514-1517.	0.9	20
56	Identification and Validation of Anaphylaxis Using Electronic Health Data in a Population-based Setting. Epidemiology, 2021, 32, 439-443.	1.2	20
57	Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System. Computers in Biology and Medicine, 2021, 135, 104517.	3.9	19
58	Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program. Vaccine, 2012, 30, 2824-2830.	1.7	18
59	Statistical, Epidemiological, and Risk-Assessment Approaches to Evaluating Safety of Vaccines Throughout the Life Cycle at the Food and Drug Administration. Pediatrics, 2011, 127, S31-S38.	1.0	17
60	Success Of Program Linking Data Sources To Monitor H1N1 Vaccine Safety Points To Potential For Even Broader Safety Surveillance. Health Affairs, 2012, 31, 2518-2527.	2.5	17
61	Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System. Drug Safety, 2013, 36, 573-582.	1.4	17
62	Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System. Pharmacoepidemiology and Drug Safety, 2018, 27, 1077-1084.	0.9	17
63	Comparison of military and civilian reporting rates for smallpox vaccine adverse events. Pharmacoepidemiology and Drug Safety, 2007, 16, 597-604.	0.9	16
64	Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: Findings from a machine learning pilot project. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1507-1517.	2.2	15
65	Adverse events after hepatitis A B combination vaccine. Vaccine, 2006, 24, 2685-2691.	1.7	14
66	Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. Vaccine, 2008, 26, 2428-2432.	1.7	14
67	An evaluation of statistical approaches to postmarketing surveillance. Statistics in Medicine, 2020, 39, 845-874.	0.8	14
68	Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children. Pediatric Infectious Disease Journal, 2011, 30, e1-e8.	1.1	13
69	Can Natural Language Processing Improve the Efficiency of Vaccine Adverse Event Report Review?. Methods of Information in Medicine, 2016, 55, 144-150.	0.7	13
70	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate "Real World" Evidence of Comparative Effectiveness and Safety. Drug Safety, 2019, 42, 1297-1309.	1.4	13
71	Automating case definitions using literature-based reasoning. Applied Clinical Informatics, 2013, 04, 515-527.	0.8	12
72	The contribution of the Vaccine adverse event Text Mining system to the classification of possible Guillain-Barré Syndrome reports. Applied Clinical Informatics, 2013, 04, 88-99.	0.8	12

#	ARTICLE	IF	CITATIONS
73	ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance. <i>Drug Safety</i> , 2021, 44, 83-94.	1.4	12
74	Identifying Similar Cases in Document Networks Using Cross-Reference Structures. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1906-1917.	3.9	10
75	Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. <i>Studies in Health Technology and Informatics</i> , 2011, 169, 564-8.	0.2	10
76	Simulating adverse event spontaneous reporting systems as preferential attachment networks. <i>Applied Clinical Informatics</i> , 2014, 05, 206-218.	0.8	9
77	Preventable Mix-ups of Tuberculin and Vaccines. <i>Drug Safety</i> , 2008, 31, 1027-1033.	1.4	8
78	Death and serious illness following influenza vaccination: a multidisciplinary investigation. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 504-511.	0.9	8
79	A pattern discovery framework for adverse event evaluation and inference in spontaneous reporting systems. <i>Statistical Analysis and Data Mining</i> , 2014, 7, 352-367.	1.4	8
80	Robustness properties of a sequential test for vaccine safety in the presence of misspecification. <i>Statistical Analysis and Data Mining</i> , 2014, 7, 368-375.	1.4	8
81	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2506-2516.	3.0	8
82	Novel algorithms for improved pattern recognition using the US FDA Adverse Event Network Analyzer. <i>Studies in Health Technology and Informatics</i> , 2014, 205, 1178-82.	0.2	7
83	Developmental regression and autism reported to the Vaccine Adverse Event Reporting System. <i>Autism</i> , 2007, 11, 301-310.	2.4	6
84	Safety assessment of recalled <i>Haemophilus influenzae</i> type b (Hib) conjugate vaccines-United States, 2007-2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 306-310.	0.9	6
85	Information Visualization Platform for Postmarket Surveillance Decision Support. <i>Drug Safety</i> , 2020, 43, 905-915.	1.4	6
86	Varicella-Zoster Vaccine. <i>New England Journal of Medicine</i> , 2007, 357, 88-90.	13.9	4
87	Perinatal Hepatitis B Transmission and Vaccination Timing in a Managed Care Cohort. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 329-333.	1.1	4
88	Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007 [Vaccine 2009;27:290-297]. <i>Vaccine</i> , 2009, 27, 6654-6655.	1.7	4
89	Perspectives on the future of postmarket vaccine safety surveillance and evaluation. <i>Expert Review of Vaccines</i> , 2014, 13, 455-462.	2.0	3
90	Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol. <i>JMIR Research Protocols</i> , 2020, 9, e21811.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Increased Confidence in Deduplication of Drug Safety Reports with Natural Language Processing of Narratives at the US Food and Drug Administration. <i>Frontiers in Drug Safety and Regulation</i> , 0, 2, .	0.5	2
92	Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 796-798.	0.2	1
93	Using real-world data to evaluate biosimilar switching. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 814-816.	0.9	0
94	Comparison of alpha-spending plans for near real-time monitoring for Guillain-Barré Syndrome after influenza vaccination during the 2010/11 influenza season. <i>Vaccine</i> , 2020, 38, 2221-2228.	1.7	0